TME PHARMA overview

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME) , a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today that its financial visibility will be extended into May 2026 through the issuance of debt via private contractual agreements with professional European investors (Investors) in exchange for €1.71 million in cash. The debt will be issued on May 28, 2025 at a discount...

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME) , a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the annual general meeting of shareholders (the AGM) of the company is convened at 03.00 p.m. CEST on June 25, 2025, at the offices of Freshfields LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands. Following the announcement on May 05, 2025, one item on...

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today that its financial visibility will be extended into May 2026 through the issuance of regular bonds to professional investors with an aggregated nominal value of €2.05 million. The bonds were issued at a discount and with attached private warrants at a 38% premium to...

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today that Diede van den Ouden plans to enlarge his stake in the company by buying shares on the market. “I want to commit myself to the success of the company and align my interests with those of other shareholders,” said Diede van den Ouden . “I am instructing these...

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today a strategic change to facilitate ongoing efforts to finance the next clinical trial for NOX-A12 through agreements with pharma or financial partners. The strategy will involve the nomination of Diede van den Ouden as the new CEO of TME Pharma N.V . at the upcoming annual...

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today its financial results for the fiscal year ending December 31, 2024, and provides a business update. The Annual Report 2024, as approved by the management and supervisory boards on April 24, 2025, is available on TME Pharma’s website ( www.tmepharma.com ). “ TME...

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that it has increased the resources allocated to the liquidity contract entrusted to Invest Securities by the contribution of €5,000 in cash. This increase, in accordance with the provisions of article 4 of the Autorité des marchés financiers (AMF) decision no....

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides results of the fifth exercise of Warrants Z and an update on the outstanding number of ordinary shares and Warrants Z as of the settlement date taking place today. The exercise of 556 Warrants Z has resulted in the issuance of 695 new shares for gross proceeds of €139. In the...